Stockreport

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Pharmaceuticals, Inc.  (AGIO) 
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.agios.com/investor-overview
PDF First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA’s Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional [Read more]